US approves Gamida's therapy to reduce infection risk in cancer patients (updated)

Gamida Cell

17/04/2023 18:32

(Adds details, shares)
       April 17 (Reuters) - The U.S. Food and Drug
Administration said on Monday it had approved Gamida Cell Ltd's
 GMDA.O  cell therapy to reduce the risk of infection in blood
cancer patients. 
    Gamida Cell's shares were up more than 40% at $1.14. 
    The company declined to comment on the therapy's pricing. 
    

 (Reporting by Pratik Jain and Raghav Mahobe in Bengaluru;
Editing by Shinjini Ganguli)
 ((Pratik.Jain@thomsonreuters.com;))